
News|Slideshows|March 31, 2022
American College of Cardiology 71st Scientific Sessions: Science Preview, April 4, 2022
Author(s)Patient Care Editorial Staff
At ACC 2022 on Sunday, 4-2, look for studies on icosapent ethyl and alirocumab, landmark research on HFrEF, and a novel anticoagulant for atrial fibrillation.
Advertisement
On the final day of ACC 2022, check out late-breaking clinical trials during 3 different sessions.
A few higlights: Edoxaban vs DAPT post-TAVR, finerenone and cardiorenal outcomes in special CVD populations, canakinumab and residual inflammatory risk, and a report on an international ACC program to improve treatment for STEMI.
Saturday, April 2, 2022 Late Breaking Clincial Trials
Sunday, April 3, 2022 Late Breaking Clincial Trials
More News from ACC on Patient Care
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
ACOG Releases New Guidance on HIV Screening and Prevention
2
2026 Dyslipidemia Guideline Expands Statin Eligibility to 21.5 Million More US Adults
3
From Amyloid Clearance to Daytime Function: Why Sleep Quality Matters for Brain Health
4





























































































































































